The Ecosystem: Polish biotechs seek solid foundations for future growth

Medical biotech in Poland is having a Goldilocks moment. Its companies are hot enough to drive a significant local ecosystem, but not so numerous that competition for public cash or talent is cut-throat. Yet there is also room for improvement, with the coverage and management of public funding seen as flawed, smart private investment scarce, academic researchers often out of synch with commercial needs and a shortage of the clinical development and regulatory skills that are needed to take drugs through to the market.